Page 400 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

378 PART IV Specific Malignancies in the Small Animal Patient

57. Mayr B, Eschborn U, Schleger W, et al.: Cytogenetic studies in a 79. Borrego JF, Huelsmeyer MK, Pinkerton ME, et al.: Neurokinin-1
canine malignant melanoma, J Comp Pathol 106:319–322, 1992. receptor expression and antagonism by the NK-1R antagonist
58. Mayr B, Schaffner G, Reifinger M, et al.: N-ras mutations in canine maropitant in canine melanoma cell lines and primary tumour tis-
VetBooks.ir 59. Mayr B, Reifinger M, Grohe D, et al.: Cytogenetic alterations in 80. Seo KW, Coh YR, Rebhun RB, et al.: Antitumor effects of cele-
sues, Vet Comp Oncol 14:210–224, 2016.
malignant melanomas, Vet J 165:169–171, 2003.
feline melanoma, Vet J 159:97–100, 2000.
cell lines, Res Vet Sci 96:482–486, 2014.
60. Mayr B, Wilhelm B, Reifinger M, et al.: Absence of p21 WAF1 and coxib in COX-2 expressing and non-expressing canine melanoma
p27 kip1 gene mutations in various feline tumours, Vet Res Com- 81. Teixeira TF, Gentile LB, da Silva TC, et al.: Cell proliferation and
mun 24:115–124, 2000. expression of connexins differ in melanotic and amelanotic canine
61. Sulaimon SS, Kitchell BE: The basic biology of malignant mela- oral melanomas, Vet Res Commun 38:29–38, 2014.
noma: molecular mechanisms of disease progression and compara- 82. Greene VR, Wilson H, Pfent C, et al.: Expression of leptin and iNOS
tive aspects, J Vet Intern Med 17:760–772, 2003. in oral melanomas in dogs, J Vet Intern Med 27:1278–1282, 2013.
62. Murakami A, Mori T, Sakai H, et al.: Analysis of KIT expression 83. Campagne C, Jule S, Alleaume C, et al.: Canine melanoma diagno-
and KIT exon 11 mutations in canine oral malignant melanomas, sis: RACK1 as a potential biological marker, Vet Pathol 50:1083–
Vet Comp Oncol 9:219–224, 2011. 1090, 2013.
63. Abou AS: Immunohistochemical expression of MCAM/CD146 in 84. Chon E, Thompson V, Schmid S, et al.: Activation of the canonical
canine melanoma, J Comp Pathol 157:27–33, 2017. Wnt/beta-catenin signalling pathway is rare in canine malignant
64. Heishima K, Ichikawa Y, Yoshida K, et al.: Circulating melanoma tissue and cell lines, J Comp Pathol 148:178–187, 2013.
microRNA-214 and -126 as potential biomarkers for canine neo- 85. Han JI, Kim Y, Kim DY, et al.: Alteration in E-cadherin/beta-
plastic disease, Sci Rep 7:2301, 2017. catenin expression in canine melanotic tumors, Vet Pathol 50:274–
65. Starkey MP, Compston-Garnett L, Malho P, et al.: Metastasis- 280, 2013.
associated microRNA expression in canine uveal melanoma, Vet 86. Brachelente C, Cappelli K, Capomaccio S, et al.: Transcriptome
Comp Oncol 18:81–89, 2017. analysis of canine cutaneous melanoma and melanocytoma reveals
66. Lee BH, Neela PH, Kent MS, et al.: IQGAP1 is an oncogenic tar- a modulation of genes regulating extracellular matrix metabolism
get in canine melanoma, PLoS One 12:e0176370, 2017. and cell cycle, Sci Rep 7:6386, 2017.
67. Ogasawara S, Honma R, Kaneko MK, et al.: Podoplanin expression 87. Chu PY, Pan SL, Liu CH, et al.: KIT gene exon 11 mutations in
in canine melanoma, Monoclon Antib Immunodiagn Immunother canine malignant melanoma, Vet J 196:226–230, 2012.
35:304–306, 2016. 88. Gillard M, Cadieu E, De BC, et al.: Naturally occurring melano-
68. Finotello R, Monne Rodriguez JM, Vilafranca M, et al.: Immunohis- mas in dogs as models for non-UV pathways of human melanomas,
tochemical expression of MDR1-Pgp 170 in canine cutaneous and Pigment Cell Melanoma Res 27:90–102, 2014.
oral melanomas: pattern of expression and association with tumour 89. Laprie C, Abadie J, Amardeilh MF, et al.: MIB-1 immunoreactivity
location and phenotype, Vet Comp Oncol 15:1393–1402, 2016. correlates with biologic behaviour in canine cutaneous melanoma,
69. Zoroquiain P, Mayo-Goldberg E, Alghamdi S, et al.: Melanocytoma- Vet Dermatol 12:139–147, 2001.
like melanoma may be the missing link between benign and malig- 90. Millanta F, Fratini F, Corazza M, et al.: Proliferation activity in
nant uveal melanocytic lesions in humans and dogs: a comparative oral and cutaneous canine melanocytic tumours: correlation with
study, Melanoma Res 26:565–571, 2016. histological parameters, location, and clinical behaviour, Res Vet Sci
70. Wei BR, Michael HT, Halsey CH, et al.: Synergistic targeted inhi- 73:45–51, 2002.
bition of MEK and dual PI3K/mTOR diminishes viability and 91. Vail DM, Macewen EG: Spontaneously occurring tumors of com-
inhibits tumor growth of canine melanoma underscoring its utility panion animals as models for human cancer, Cancer Invest 18:781–
as a preclinical model for human mucosal melanoma, Pigment Cell 792, 2000.
Melanoma Res 29:643–655, 2016. 92. Esplin DG: Survival of dogs following surgical excision of histo-
71. Lin W, Modiano JF, Ito D: Stage-specific embryonic antigen: logically well-differentiated melanocytic neoplasms of the mucous
determining expression in canine glioblastoma, melanoma, and membranes of the lips and oral cavity, Vet Pathol 45:889–896, 2008.
mammary cancer cells, J Vet Sci 18:101–104, 2017. 93. Spangler WL, Kass PH: The histologic and epidemiologic bases
72. Abou AS, Anwar S, Yanai T, et al.: Immunohistochemical analysis for prognostic considerations in canine melanocytic neoplasia, Vet
of CD146 expression in canine skin tumours, Histol Histopathol Pathol 43:136–149, 2006.
31:453–459, 2016. 94. Bergin IL, Smedley RC, Esplin DG, et al.: Prognostic evaluation of
73. Noguchi S, Mori T, Nakagawa T, et al.: DNA methylation contrib- Ki67 threshold value in canine oral melanoma, Vet Pathol 48:41–53,
utes toward silencing of antioncogenic microRNA-203 in human 2011.
and canine melanoma cells, Melanoma Res 25:390–398, 2015. 95. Henry CJ, Brewer Jr WG, Whitley EM, et al.: Canine digital
74. Bongiovanni L, D’Andrea A, Porcellato I, et al.: Canine cutane- tumors: a Veterinary Cooperative Oncology Group retrospective
ous melanocytic tumours: significance of beta-catenin and survivin study of 64 dogs, J Vet Intern Med 19:720–724, 2005.
immunohistochemical expression, Vet Dermatol 26:270–e59, 2015. 96. Wobeser BK, Kidney BA, Powers BE, et al.: Diagnoses and clini-
75. Kawabe M, Baba Y, Tamai R, et al.: Profiling of plasma metabolites cal outcomes associated with surgically amputated canine digits
in canine oral melanoma using gas chromatography-mass spec- submitted to multiple veterinary diagnostic laboratories, Vet Pathol
trometry, J Vet Med Sci 77:1025–1028, 2015. 44:355–361, 2007.
76. Poorman K, Borst L, Moroff S, et al.: Comparative cytogenetic 97. Marino DJ, Matthiesen DT, Stefanacci D, et al.: Evaluation of
characterization of primary canine melanocytic lesions using array dogs with digit masses: 117 cases (1981-1991), J Am Vet Med Assoc
CGH and fluorescence in situ hybridization, Chromosome Res 207:726–728, 1995.
23:171–186, 2015. 98. Piliang MP: Acral lentiginous melanoma, Clin Lab Med 31:281–
77. Noguchi S, Kumazaki M, Mori T, et al.: Analysis of microRNA-203 288, 2011.
function in CREB/MITF/RAB27a pathway: comparison between 99. Smedley RC, Spangler WL, Esplin DG, et al.: Prognostic mark-
canine and human melanoma cells, Vet Comp Oncol 14:384–394, ers for canine melanocytic neoplasms: a comparative review of the
2016. literature and goals for future investigation, Vet Pathol 48:54–72,
78. Guth AM, Deogracias M, Dow SW: Comparison of cancer stem 2011.
cell antigen expression by tumor cell lines and by tumor biopsies 100. Wiggans KT, Reilly CM, Kass PH, et al.: Histologic and immuno-
from dogs with melanoma and osteosarcoma, Vet Immunol Immu- histochemical predictors of clinical behavior for feline diffuse iris
nopathol 161:132–140, 2014. melanoma, Vet Ophthalmol 19(Suppl 1):44–55, 2016.